Information Provided By:
Fly News Breaks for February 25, 2020
Feb 25, 2020 | 07:16 EDT
H.C. Wainwright analyst Edward White raised the firm's price target on Aeglea BioTherapeutics to $24 from $20 and keeps a Buy rating on the shares. The analyst believes pegzilarginase will launch in the U.S. in 2022, followed by a launch in Europe. He estimates pegzilarginase sales of $13M in 2022, growing to $270M in 2028.
News For AGLE From the Last 2 Days
There are no results for your query AGLE